Testing a new dose of tafenoquine for vivax malaria
Treatments studied
Part of Infections clinical trials.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have vivax malaria confirmed by a blood test, with no other types of malaria.
- You need a G6PD test that shows normal enzyme activity (at least 70% of the average for healthy males).
- You must have a fever (temperature 99.5°F or higher) or have had one in the last 48 hours.
- You cannot be pregnant or breastfeeding.
- You must live in the study area and be willing to come back for check-ups over 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well the drug primaquine works for people with vivax malaria who have intermediate or low levels of an enzyme called G6PD. It aims to find safe and effective treatment options for this group.
This trial tests a combination of antimalarial drugs (tafenoquine plus artemisinin-based combination therapies) to see if it's safe and effective for treating vivax malaria. Participating may help clear the infection and prevent it from coming back.
This study tests how the malaria medicine tafenoquine is processed in the bodies of young children with vivax malaria. It helps find the right dose for small children and ensures the treatment is safe and effective.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
This trial tests a shorter course of the drug primaquine to prevent relapse of vivax malaria, a recurring type of malaria. It may offer a faster recovery with fewer doses.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
Hear when a new Vivax Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.